Alx Oncology Holdings Inc is a pioneering force in the field of immuno-oncology, dedicated to crafting innovative cancer therapies. At the forefront of its promising pipeline is evorpacept, a novel CD47 blocking agent designed to enhance the body's immune response against cancer. This therapeutic is being explored in combination with other treatments across a spectrum of cancers, including leukemia and breast cancer. The company is also advancing ALTA-002, aiming to harness both innate and adaptive immune responses to cancer. With strategic collaborations, including with Merck and Zymeworks, Alx Oncology is pushing the boundaries of cancer treatment from its base in South San Francisco, California.